Rationale and design of a phase III trial of adjuvant sequential epirubicin/ cyclophosphamide and taxane versus concurrent epirubicin/taxane in operable node-positive breast cancer. [electronic resource]
Producer: 20050628Description: S52-6 p. digitalISSN:- 1526-8209
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Breast Neoplasms -- drug therapy
- Chemotherapy, Adjuvant
- Clinical Trials, Phase III as Topic
- Cyclophosphamide -- administration & dosage
- Drug Administration Schedule
- Epirubicin -- administration & dosage
- Female
- Humans
- Research Design
- Survival Analysis
- Taxoids -- administration & dosage
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.